GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (LTS:0A8E) » Definitions » Sale Of Business

Xeris Biopharma Holdings (LTS:0A8E) Sale Of Business : $0.0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Xeris Biopharma Holdings Sale Of Business?

Xeris Biopharma Holdings's sale of business for the three months ended in Sep. 2024 was $0.0 Mil. It means Xeris Biopharma Holdings gained $0.0 Mil from selling business. Xeris Biopharma Holdings's sale of business for the trailing twelve months (TTM) ended in Sep. 2024 was $0.0 Mil.

Compared with last quarter ($0.0 Mil in Jun. 2024 ), Xeris Biopharma Holdings gained the same money from selling business in Sep. 2024 ($0.0 Mil).


Xeris Biopharma Holdings Sale Of Business Historical Data

The historical data trend for Xeris Biopharma Holdings's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Sale Of Business Chart

Xeris Biopharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Business
Get a 7-Day Free Trial - - 38.47 - -

Xeris Biopharma Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sale Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Xeris Biopharma Holdings Sale Of Business Calculation

The amount earned to sell business.


Sale Of Business for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xeris Biopharma Holdings Sale Of Business Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


Xeris Biopharma Holdings Business Description

Traded in Other Exchanges
Address
1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Xeris Biopharma Holdings Headlines

No Headlines